Paper Details

  1. Home
  2. Paper Details

Identification of a new azoreductase driven prodrug from bardoxolone methyl and 5-aminosalicylate for the treatment of colitis in mice.

Author: GongYan, HuangZhang-Jian, MouYi, QiaoXin, WenXiao-Dong, ZhangYi-Hua

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study presents the design, synthesis, and biological evaluation of a new azoreductase-driven prodrug, CDDO-AZO, for the local treatment of ulcerative colitis. CDDO-AZO showed promising anti-colitis effects in a mouse model.
Paper Details　
Original Abstract of the Article :
For local treatment of ulcerative colitis, a new azoreductase driven prodrug CDDO-AZO from bardoxolone methyl (CDDO-Me) and 5-aminosalicylate (5-ASA) was designed, synthesized and biologically evaluated. It is proposed that orally administrated CDDO-AZO is stable before reaching the colon, while it ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1875-5364(21)60055-9

データ提供：米国国立医学図書館（NLM）

CDDO-AZO: A New Prodrug for Colitis Treatment: A Journey Through the Desert of Inflammation

Ulcerative colitis, a chronic inflammatory bowel disease, can feel like a scorching desert of pain and discomfort. This research, like a dedicated explorer searching for a healing oasis, investigates the potential of a new azoreductase-driven prodrug, CDDO-AZO, for the treatment of colitis in mice. The researchers meticulously designed, synthesized, and evaluated the effects of CDDO-AZO, comparing it to existing treatments like olsalazine and a combination of CDDO-Me and 5-ASA.

A Promising Oasis: CDDO-AZO Shows Potential for Colitis Treatment

The study found that CDDO-AZO significantly attenuated inflammatory colitis symptoms in mice with DSS-induced chronic colitis. The researchers highlight the prodrug's ability to fragment into CDDO-Me and 5-ASA, both known for their anti-colitis effects, upon exposure to azoreductase in the colon. It's like finding a hidden spring in the desert, offering a targeted and potentially more effective solution to a challenging condition.

A New Path to Healing: Exploring Novel Treatments for Colitis

This research provides a promising starting point for further exploration of CDDO-AZO as a potential treatment for ulcerative colitis. The study's findings suggest that this novel prodrug may offer a safer and more effective alternative to existing treatments, potentially improving patient outcomes and quality of life.

Dr. Camel's Conclusion

This research provides valuable insights into the potential of CDDO-AZO as a novel prodrug for the treatment of colitis in mice. The study's findings suggest that this compound may offer a safer and more effective alternative to existing treatments. It's a reminder that in the vast desert of inflammatory bowel disease research, we must continue to explore innovative approaches to address the needs of individuals facing this challenging condition.

Date :
  1. Date Completed 2021-10-20
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

34247779

DOI: Digital Object Identifier

10.1016/S1875-5364(21)60055-9

Related Literature

Article Analysis
・Effects of olsalazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.